Medtronic initiates global pivotal study of cardiac pacing in a new patient population

Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (hfpef) who have limited treatment options today galway, ireland , sept. 15, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for the treatment of patients with heart failure with preserved ejection fraction (elevate-hfpef, nct06678841).
MDT Ratings Summary
MDT Quant Ranking